TNiC Methodology
How compounds are selected, evidence is graded, biomarkers are modeled, and conflicts of interest are managed. Published for full transparency.
What this is
Full published methodology — compound curation, evidence grading rubric, biomarker modeling, and conflict-of-interest policy.
Why it matters
Hub tab summaries are not enough for physician or researcher review. This page is the complete audit document.
What to do next
Read tier assignment criteria, then cross-check your stack compounds against the Evidence tab definitions.
The grading ladder
100 graded compounds · re-evaluated quarterly
Tier A — Clinical Evidence
Human randomized or controlled trial with measured biomarker or healthspan outcomes.
- Peer-reviewed human RCT or controlled trial
- Measurable outcome reported
- Independent replication or multi-trial consensus
- Safety profile in human subjects
Tier B — Mechanistic + Emerging Human
Strong mechanistic data with at least one human pharmacokinetic or pilot study.
- Characterized mechanism in human cells/tissue
- Human PK or pilot data exists
- Consistent preclinical healthspan data
- Used in established protocols
Tier C — Preclinical Only
Animal or in-vitro evidence only. Flagged — not recommended as stack foundation.
- Animal or in-vitro mechanistic evidence
- No human longevity outcomes
- Included only when mechanism aligns with hallmark
- Clearly labeled as preclinical
Evidence recency
Canonical citation registry
- 30
- Traceable sources
- 2021
- Median year
- 63%
- Since 2020
- 2006–2026
- Span
Compound Selection Methodology
Mechanism First
Must target a mapped hallmark or defense pathway. Trend-driven inclusion rejected.
Bioavailability Verified
Formulation must achieve meaningful plasma levels. Inferior forms (racemic ALA, oxide minerals) excluded.
PubMed Traceable
Primary literature required. Marketing claims without citations are rejected.
Dose-Response Validated
Dosing from clinical trials. AM/PM timing from absorption pharmacokinetics.
Synergy Tested
Stack pairs evaluated for pathway overlap and interaction risk before recommendation.
Evidence Grading Process
Assign Initial Tier
Literature review assigns A/B/C based on human vs. preclinical data.
Independent Check
Second review confirms PMID validity and outcome relevance.
Public Labeling
Tier displayed on every compound surface. No hidden downgrades.
Quarterly Re-Review
New trials trigger tier updates. Changes logged in Update History.
Biomarker & Bio Age Modeling
Lifestyle Inputs
Age, stress, sleep, exercise feed defense pathway priority calculator.
Stack Boost
Selected compounds apply modeled biomarker improvements — clearly labeled as projections.
Lab Override
When users log real lab data in /labs, actual values supersede projections for recommendations.
Never Diagnostic
Modeled biological age is directional only. Not a laboratory diagnostic.
Conflict of Interest Policy
No Pay-for-Placement
Brands cannot purchase inclusion or tier upgrades.
Transparent Affiliate
TNiC may earn a commission on verified picks via affiliate links — disclosed here and at point of purchase. Commission never influences product selection, evidence tiers, or buyer-guide criteria.
No Proprietary Products
TNiC does not manufacture supplements. Independent curation only.
By the numbers
The evidence base behind every grade
How to check this
The rest of the accountability trail.
TNiC is educational only — not medical advice. Consult your physician before starting any protocol.